a83e78c0-8b1b-4576-aace-4bee1dee5046
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.340
- HEDGEHOG_SIGNALING+0.330
- MYOGENESIS+0.320
- ANGIOGENESIS+0.260
- MITOTIC_SPINDLE+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.240
- UV_RESPONSE_DN+0.210
- APICAL_JUNCTION+0.170
- G2M_CHECKPOINT+0.150
- APICAL_SURFACE+0.140
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.690
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.550
- MYC_TARGETS_V1-0.520
- MTORC1_SIGNALING-0.440
- PROTEIN_SECRETION-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.430
- DNA_REPAIR-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- FATTY_ACID_METABOLISM-0.380
- MYC_TARGETS_V2-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A26I-01B-06R-A22O-07 | — | D | 0.890 |
| 2 | SRR13311176 | — | — | 0.874 |
| 3 | SRR1313107 | — | F | 0.868 |
| 4 | MBCProject_0589_T1_RNA | — | A | 0.860 |
| 5 | X8de42096.ef3e.4864.8ee1.2ee7672c1c82 | — | cohortSQ1 | 0.859 |
| 6 | X84315f98.9366.4174.be54.3cdd1fd9db07 | — | cohortA1 | 0.854 |
| 7 | TCGA-58-8388-01A-11R-2326-07 | — | cohortSQ1 | 0.849 |
| 8 | d7bbb44a-3fe0-4455-99d0-90be213f2a31 | — | — | 0.847 |
| 9 | BS_YK6VQ9SJ | DNET | — | 0.844 |
| 10 | 3383d8e1-d61d-4346-a589-007ad2829e36 | — | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |